The Competition Commission unanimously approved the notification concerning the acquisition of joint control by Strix Asset Management Ltd and Farallon Capital Management L.L.C. over Euromedica, a company offering medical services in Greece.

The transaction meets the thresholds set by competition law and does not have a European dimension. It involves the markets of private general clinics and private diagnostic centers within the geographic scope of Greece.

No affected markets were identified horizontally or vertically, as the criteria for market share concentration were not met. The concentration does not raise conglomerate effects concerns.

The Competition Commission, in a unanimous decision, approved the acquisition of joint control by Strix Asset Management Ltd and Farallon Capital Management L.L.C. over Euromedica, as it does not raise serious doubts regarding its compatibility with competition requirements in the relevant markets.